key: cord-1051239-iui956w5
authors: Khatamzas, E.; Rehn, A.; Muenchhoff, M.; Hellmuth, J.; Gaitzsch, E.; Weiglein, T.; Georgi, E.; Scherer, C.; Stecher, S.; Weigert, O.; Girl, P.; Zange, S.; Keppler, O. T.; Stemmler, J.; Bergwelt-Baildon, M.; Woelfel, R.; Antwerpen, M.
title: Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.10.20248871
sha: 675a4a6d54b251369ea46ca8aeb00d76d2638dbc
doc_id: 1051239
cord_uid: iui956w5

Prolonged shedding of infectious SARS-CoV-2 has recently been reported in a number of immunosuppressed individuals with COVID-19. Here, we describe the detection of high levels of replication-competent SARS-CoV-2 in specimens taken from the respiratory tract of a B-cell depleted patient up to 154 days after initial COVID-19 diagnosis concomitant with the development of high mutation rate. In this patient, a total of 11 nonsynonymous mutations were detected in addition to the Y144 deletion in the spike protein of SARS-CoV-2. Virus evolution studies revealed a dramatic diversification in viral population coinciding with treatment with convalescent plasma and clinical respiratory deterioration. Our findings highlight the urgent need for continuous real-time surveillance of genetic changes of SARS-CoV-2 adaptation alongside immunological investigations in patients with severely compromised humoral responses who may shed infectious virus over prolonged periods of time.

Since the end of 2019, the severe respiratory disease Coronavirus disease 2019 (COVID-19) [1] that originated in Wuhan, China, has developed into a pandemic with devastating effects.

According to the John Hopkins University there are to this date (Dec. 22, 2020) over 77.4 million COVID-19 cases and 1.7 million deaths worldwide [2] .

In December 2020, a new emergent variant of SARS-CoV-2 was reported in the United Kingdom [3] with a postulated higher infectivity and thus transmission rate [4] . Unique national and international collaborative effort has allowed sequencing data of full-length SARS-CoV-2 genomes to be shared immediately allowing both predictions of structural changes of specific viral proteins [5] [6] [7] [8] important for immune recognition and the use of data for molecular epidemiology studies [9] . One of the possible sources for increased genetic diversity seen within SARS-CoV-2 may be individuals with prolonged viral infection due to underlying immunosuppression. Recently a number of single case reports have shown within host genetic diversity arising in the absence of immunological pressure and upon treatment with COVID-19 specific treatment in immunocompromised hosts [10] [11] . In the context of the novel B 1.1.7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01. 10 .20248871 doi: medRxiv preprint lineage a combination of mutations and deletions within spike were described in such a patient [10] [11] .

We have recently reported our observations with a cohort of six B-cell depleted patients with COVID-19 (BLD-2020-010058, under review). Within this study, we observed notable findings in one of those patients, who exhibited a protracted, eventually fatal clinical course characterised by the presence of high concentrations of replication-competent SARS-CoV-2 in the respiratory tract for more than 134 days. Here, we present analysis of the viral evolution of samples from this patient over time with increased detectable rate of mutation in comparison to two other Bcell depleted patients as well as the general population of SARS-CoV-2 infected individuals, thus suggesting a unique interplay of host and viral factors.

A woman (patient A) in her 70ies was hospitalised with COVID-19 and severe ARDS. She had been feeling unwell with worsening upper respiratory symptoms for two weeks prior to presentation requiring high flow oxygen on admission. On transfer to our center endotracheal intubation and ventilation were initiated and she was managed in our intensive care unit until her death 5 months later. Her past medical history was significant for follicular lymphoma that had been treated with a total of three cycles of standard chemotherapy cyclophosphamide, doxorubicin, vincristine and prednisone in combination with the B-cell depleting anti-CD20 antibody obinituzumab up to a month prior to presentation.

COVID-19-directed treatment initially included steroids as well as administration of convalescent plasma ( Figure 1 ). Therapy with remdesivir was deemed unsafe due to existing renal failure and known hypersensitivity to sulfobutylether-β-cyclodextrin.

Clinical upper and lower respiratory tract specimens obtained from patient A showed low Ct values and high viral concentrations throughout until date of death on day 156 following diagnosis ( Figure 1 ). In keeping with this SARS-CoV-2 could be successfully isolated in Vero E6 cell cultures from all 16 patient samples examined in this study. Of note, the first samples submitted for viral cultures for patient A were on day 20, which although later in course of infection, we henceforth refer to as day 0.

At the same time we were also treating other B-cell depleted lymphoma patients within our unit (BLD-2020-010058, under review), two of these (patients B and C) protracted severe COVID-19 course with ARDS following nosocomial transmission of SARS-CoV-2 from a presumably . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.10.20248871 doi: medRxiv preprint common source. Eventually, both recovered fully and were able to be discharged from hospital care.

We were able to generate 16 high quality genomes of SARS-CoV-2 isolated from all three patients from successive time points (10 from patient A and 3 from patients B and C, respectively). All genomes were generated from samples with replication-competent SARS-CoV-2. The genomes hold at least 29685 nucleotides in length, which is more than 99% of the SARS-CoV-2 genome with a sequencing depth of usually more than 1000-fold (mean: 812-fold, min: 308-fold) ( Table 1 ). Missing nucleotides are only located at the outermost ends.

All mutations and mutational events are listed in Supplemental Data Table 1 Table 1 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. Table 2 ).

So far, only little detailed knowledge of immunosuppressed COVID-19 patients is available.

Recent data has described significantly increased mutation rate and accumulation of these mutations within a short period of time in single case reports [10] [11] [12] . As SARS-CoV-2 was not only detectable but also cultivable from respiratory tract samples over such a long period of time, comprehensive sequencing data of SARS-CoV-2 could be generated from this single severely immunocompromised host. These sequences show an unusually large number of nucleotide changes and deletions in addition to an unusually high ratio of nonsynonymous mutational events. In our study, the ratio of non-synonymous to synonymous mutations is 3 This is observed without any detectable SARS-CoV-2 specific antibody response by the host and after administration of convalescent plasma, similar to the findings described by Kemp et al [12] . The therapeutic efficacy of convalescent plasma is still under investigation in multiple clinical trials but so far has been disappointing [13] . Our data suggests that its use should be . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.10.20248871 doi: medRxiv preprint (nt23604) and N501Y (nt23063), this seems to be unique at the moment [14] . In contrast to this, our samples show a deletion in the spike protein at Y144, which is not only observed in the emerging lineage B1.1.7 [4] , but has also been described in a sample from 30 July 2020 in England (England/SHEF-C71F3/2020) [14] . As more detailed metadata of this strain is currently not available, one speculative explanation may be that these nucleotide changes were also generated in a chronically infected host.

Based on the assumption that circulating SARS-CoV-2 lineages accumulate nucleotide mutations at a rate of about 1-2 mutations per month [16] , resulting in about 23,638 In conclusion, we find that detailed characterization of the interaction between SARS-CoV-2 and the host in immunocompromised, particularly B-cell-depleted patients, provides a rare opportunity to follow viral adaptive evolution during the course of chronic infection. This will be . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Patient data were pseudonymized for analysis and the study was approved by the local ethics committees (No: 20-245). Written informed consent was obtained from each patient or authorized by proxy before any study related procedure.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. For classification of mutations, please refer to Suppl_Data_File1.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 15, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.10.20248871 doi: medRxiv preprint

The Species Severe Acute Respiratory Syndrome-Related Coronavirus : Classifying 2019-NCoV and Naming It SARS-CoV-2

An Interactive Web-Based Dashboard to Track COVID-19 in Real Time

ECDC Rapid Increase of a SARS-CoV-2 Variant with Multiple Spike Protein Mutations Observed in the United Kingdom

Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations

Remdesivir Failure with SARS-CoV-2 RNA-Dependent RNA-Polymerase Mutation in a B-Cell Immunodeficient Patient with Protracted Covid-19

Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus

SARS-CoV-2 Samples May Escape Detection Because of a Single Point Mutation in the N Gene

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Front

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Recurrent Emergence and Transmission of a SARS-CoV-2 Spike Deletion Δ H69/ΔV70

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Nextstrain: Real-Time Tracking of Pathogen Evolution

Neutralising Antibodies Drive Spike Mediated SARS-CoV-2 Evasion

Temporal Signal and the Phylodynamic Threshold of SARS-CoV-2

We greatly acknowledge all the colleagues working on the intensive care unit at the LMU